10:15 AM EST - Psyched Wellness Ltd. : Announced that the company and its Clinical Research Organization partner, KGK Science, has commenced the next preclinical trial study with AME-1. This new study is a 14-day oral toxicity study of AME-1. It will provide the level of dose(s) that will be selected and administered for a subsequent long term 90-day oral toxicity study. The importance of this study is to determine dose-dependent effects along with determining the highest dose that is safe to use for a longer-term study. This is another key milestone in the further understanding of the effects of Psyched Wellness' AME-1 extract under a scientific methodology in pursuit of a safe dose for human consumption. Psyched Wellness Ltd.
shares C.PSYC are trading down 2 cents at $0.29.
